Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.37 |
| ▸ | GPR84 | Q9NQS5 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL200036 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL199107 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL101879 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL199400 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL201036 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL101902 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL101426 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL201404 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL103378 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR | |
| SCHEMBL101715 | 1.00 | LMNA (0.52) | LMNADNM1ALDH1A1TDP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 200 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110637023-B | Dibenzopyrrole methine boron chelate compound, near infrared light absorbing material, thin film, and organic electronic device | 日本化药株式会社 | 2022-07-08 | — | — | CN | claimed |
| US-8901258-B2 | Copolymers for solar cells based on acridonic units | ENI S.P.A. (IT) | 2014-12-02 | — | — | US | claimed |
| CN-102918033-B | Aromatic monomers deriving from glycerol units, process for their preparation and use thereof for the preparation of water-soluble conjugated polymers | ENI SPA | 2014-08-06 | — | — | CN | claimed |
| EP-2513198-B1 | COPOLYMERS FOR SOLAR CELLS BASED ON ACRIDONIC UNITS | ENI SPA (IT) | 2013-12-04 | — | — | EP | claimed |
| US-20130001474-A1 | COPOLYMERS FOR SOLAR CELLS BASED ON ACRIDONIC UNITS | ENI S.P.A. (IT) | 2013-01-03 | — | — | US | claimed |
| EP-2513198-A1 | COPOLYMERS FOR SOLAR CELLS BASED ON ACRIDONIC UNITS | ENI S.p.A. (IT) | 2012-10-24 | — | — | EP | claimed |
| WO-2011072876-A1 | COPOLYMERS FOR SOLAR CELLS BASED ON ACRIDONIC UNITS | ENI S.P.A. (IT) | 2011-06-23 | — | — | WO | claimed |
| WO-2011066954-A1 | π-CONJUGATED POLYMERS CONTAINING FLUOROARYLVINYLEDENE UNITS AND RELATIVE PREPARATION PROCESS | ENI S.P.A. (IT) | 2011-06-09 | — | — | WO | claimed |
| CN-118201905-A | Cationic lipid | 武田药品工业株式会社 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024112546-A1 | LIQUID WEIGHTING AGENTS FOR OIL-BASED FLUIDS | ALBEMARLE CORPORATION (US) | 2024-05-30 | — | — | WO | disclosed |
| EP-3666777-B1 | DIBENZOPYRROMETHENE BORON CHELATE COMPOUND, NEAR-INFRARED LIGHT-ABSORBING MATERIAL, THIN-FILM, AND ORGANIC ELECTRONIC DEVICE | NIPPON KAYAKU KK (JP) | 2023-10-11 | — | — | EP | disclosed |
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-10-05 | — | — | US | disclosed |
| CN-110073507-B | Organic semiconductor composition, organic thin film, and organic thin film transistor | 日本化药株式会社 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023085299-A1 | CATIONIC LIPID | 武田薬品工業株式会社 | 2023-05-19 | — | — | WO | disclosed |
| EP-0353047-A2 | Use of imidazopyrazole derivatives as analgesics and anti-inflammatory agents | Sankyo Company Limited (JP) | 1990-01-31 | — | — | EP | disclosed |
| EP-0350315-A1 | Rhizoxin derivates and their use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1990-01-10 | — | — | EP | disclosed |
| US-4791128-A | Rhizoxin esters and salts, their pharmaceutical use as anti-tumor agents | SANKYO COMPANY LIMITED (JP) | 1988-12-13 | — | — | US | disclosed |
| EP-0218310-A2 | Rhizoxin derivatives, their preparation and pharmaceutical use | SANKYO COMPANY LIMITED (JP) | 1987-04-15 | — | — | EP | disclosed |
| US-4624899-A | Novel organopolysiloxane compositions useful as mold release coatings | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1986-11-25 | — | — | US | disclosed |
| CN-86102020-A | The preparation method of rhizoxin derivatives and in pharmaceutically application | — | 1986-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310419-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | SCD, SCD5, CPT1B | LMNA 2601/4885DNM1 1277/4885ALDH1A1 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.